Buscar resultados de ensayos clínicos
Essential Thrombocythemia - 25 Studies Found
Estado | Estudiar |
Completed |
Nombre del estudio: Anagrelide Retard in Essential Thrombocythemia Condición: Essential Thrombocythemia Fecha: 2014-02-13 Intervenciones:
|
Not yet recruiting |
Nombre del estudio: Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea Condición: Essential Thrombocythemia Fecha: 2017-04-17 Intervenciones:
|
Completed |
Nombre del estudio: French Observational Xagrid (FOX) Study In Adult Patients With Essential Thrombocythemia Condición: Essential Thrombocythemia Fecha: 2010-08-26 |
Completed |
Nombre del estudio: Anagrelide vs. Hydroxyurea - Efficacy and Tolerability Study in Patients With Essential Thrombocythaemia Condición: Essential Thrombocythaemia Fecha: 2010-02-08 Intervenciones:
|
Completed |
Nombre del estudio: The Pharmacokinetics of Anagrelide in Elderly and Young Patients With Essential Thrombocythaemia (ET) Condición: Essential Thrombocythaemia Fecha: 2006-12-19 Intervenciones: Drug: anagrelide hydrochloride Anagrelide hydrochloride 0.5 mg per capsule; patients will be stable on a |
Completed |
Nombre del estudio: Anagrelide Retard vs. Placebo: Efficacy and Safety in "At-risk" Patients With Essential Thrombocythaemia Condición: Essential Thrombocythaemia Fecha: 2010-10-28 Intervenciones:
|
Completed |
Nombre del estudio: Pediatric Disease Registry in Essential Thrombocythaemia (ET) Condición: Essential Thrombocythemia (ET) Fecha: 2010-09-08 |
Completed |
Nombre del estudio: Long-term Safety of SPD422 in Japanese Adults With Essential Thrombocythaemia Condición: Essential Thrombocythemia (ET) Fecha: 2011-10-31 Intervenciones: Drug: SPD422 (anagrelide hydrochloride) Subjects will be continued on the dose of anagrelide that contro |
Not yet recruiting |
Nombre del estudio: Hydroxyurea Versus Aspirin and Hydroxyurea in Essential Thrombocythemia Condición:
Fecha: 2015-10-13 Intervenciones:
|
Recruiting |
Nombre del estudio: Myelofibrosis and Essential Thrombocythemia Observational Study (MOST) Condición:
Fecha: 2016-11-01 |